AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer
Both
Colorectal Cancer
Trial Information
AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Patients with histologically confirmed metastatic colorectal cancer who will receive
Avastin in combination with first-line fluoropyrimidine-based chemotherapy
Exclusion Criteria:
- Patients not qualified for Avastin treatment according to the local label
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Overall survival from the time of starting first-line therapy
Outcome Time Frame:
approximately 3.5 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Taiwan: Food and Drugs Authority
Study ID:
ML28233
NCT ID:
NCT01712347
Start Date:
October 2012
Completion Date:
May 2016
Related Keywords:
- Colorectal Cancer
- Colorectal Neoplasms
Name | Location |
|---|
